259 related articles for article (PubMed ID: 32196533)
1. Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
Boucau J; Das J; Joshi N; Le Gall S
PLoS Pathog; 2020 Mar; 16(3):e1008442. PubMed ID: 32196533
[TBL] [Abstract][Full Text] [Related]
2. The Activation State of CD4 T Cells Alters Cellular Peptidase Activities, HIV Antigen Processing, and MHC Class I Presentation in a Sequence-Dependent Manner.
Boucau J; Madouasse J; Kourjian G; Carlin CS; Wambua D; Berberich MJ; Le Gall S
J Immunol; 2019 May; 202(10):2856-2872. PubMed ID: 30936293
[TBL] [Abstract][Full Text] [Related]
3. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
Front Immunol; 2018; 9():3162. PubMed ID: 30723480
[TBL] [Abstract][Full Text] [Related]
4. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8
Mota TM; McCann CD; Danesh A; Huang SH; Magat DB; Ren Y; Leyre L; Bui TD; Rohwetter TM; Kovacs CM; Benko E; MacLaren L; Wimpelberg A; Cannon CM; Hardy WD; Safrit JT; Jones RB
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051267
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
6. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
Gupta V; Dixit NM
PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
[TBL] [Abstract][Full Text] [Related]
7. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
8. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
[TBL] [Abstract][Full Text] [Related]
9. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
10. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
[TBL] [Abstract][Full Text] [Related]
13. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
[TBL] [Abstract][Full Text] [Related]
14. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
15. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
Covino DA; Desimio MG; Doria M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
[TBL] [Abstract][Full Text] [Related]
17. The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal.
Richard K; Schonhofer C; Giron LB; Rivera-Ortiz J; Read S; Kannan T; Kinloch NN; Shahid A; Feilcke R; Wappler S; Imming P; Harris M; Brumme ZL; Brockman MA; Mounzer K; Kossenkov AV; Abdel-Mohsen M; Andrae-Marobela K; Montaner LJ; Tietjen I
J Biol Chem; 2020 Oct; 295(41):14084-14099. PubMed ID: 32788215
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
19. T cell toxicity of HIV latency reversing agents.
Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
